Pharmaceutical Lifecycle Management Course: Making The Most Of Each And Every Brand, 5-6 June 2013, Basel
The global research-based pharmaceutical industry lies increasingly between the “rock” of empty pipelines and the “hard place” of cost containment and more aggressive generic competition. In this environment it is essential to exploit the whole spectrum of available lifecycle management (LCM) options to maximize the performance of existing brand assets.
EBCG’s Pharmaceutical Lifecycle Management Course (5-6 June, Basel) strives to critically assess all of these options, looking at past, concrete examples that have been successful – and those that have been unsuccessful – and evaluating those that will continue to be sustainable going forward. At the end of the two days, attendees will be ready to go back to their companies to re-evaluate and optimize the lifecycle plans of their marketed products and developmental projects.
The first day looks at the overall environment in which lifecycle management strategies must deliver, and then examines in detail each of the technical components in the management of an overall lifecycle: regulatory and legal aspects; patents and other exclusivities; indication expansion and sequencing; reformulation, new routes of administration and drug delivery; fixed-dose combinations; modified chemistries, and much more. Day 1 will also look at how to turn various options into robust winning strategies, as well as describe a proven process for creating an actual LCM Plan, and provide tips on how to ensure that senior management buys into that plan.
The second day switches from the more technical side of LCM to look at commercial options for optimizing brand performance over the whole lifecycle. It will cover areas like geographical expansion and optimization, OTC switching, brand loyalty and service programs, strategic pricing strategies, the value of LCM projects in the overall R&D portfolio and the management of mature (post-patent) product portfolios. Day 2 also will consider all of the options for brand companies to compete or collaborate with the generic drug industry – including acquisition, the creation of an in-house generics unit, settlements, authorized generics, API supply agreements, private labeling, and so on.